American taxpayers footed the bill for at least $1.8 trillion in federal and state health care expenditures in 2022 — about 41% of the nearly
In a recent podcast interview, Robert F. Kennedy Jr. shared his perspectives on the potential of psychedelics as a mental health treatment. This revelation coincides
Share this article More biologics are anticipated to enter the market in the coming years. Credit: SciePro via Shutterstock. The increase in inflammatory bowel disease
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced that the special meeting of
Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. Good morning. Today we have Andrew Joseph’s
Share this article Credit: Michael Vi / Shutterstock.com US-based Lantheus and POINT Biopharma have announced positive topline data from the Phase III trial investigating prostate
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, a hospital in
Share this article Image: Vitalii Vodolazskyi via Shutterstock. The Gaucher disease market is expected to grow at a compound annual growth rate (CAGR) of 0.79%
Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are enveloping the Pharmalot campus, where
Researchers identified 5-hydroxytryptamine 2A (5-HT2A) receptor (5-HT2AR) signaling pathways associated with psychedelic potential.